Dyadic Announces Research, License and Collaboration Agreement with Janssen for the Manufacture of Therapeutic Protein Candidates using its C1 Platform
17 déc. 2021 07h00 HE
|
Dyadic International, Inc.
JUPITER, Fla., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further...
Neurological Biomarkers Market by Application, by Type, by End-use, by Region and Forecasts to 2028
06 déc. 2021 06h58 HE
|
Research and Markets
Dublin, Dec. 06, 2021 (GLOBE NEWSWIRE) -- The "Neurological Biomarkers Market Size, Share & Trends Analysis Report By Application (Alzheimer's, Parkinson's), By Type (Genomic, Proteomic), By...
Improving Social Equity in Dementia Prevention and Care
30 nov. 2021 08h00 HE
|
Posit Science
WASHINGTON, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Jeff Zimman, Co-Founder of Posit Science, which makes the brain training app BrainHQ, will address the annual What’s Next Longevity Innovation Summit in...
Athira Pharma Presents Overview and Update from ACT-AD and LIFT-AD Trials of ATH-1017 in mild-to-moderate Alzheimer’s Disease at CTAD Conference
10 nov. 2021 11h50 HE
|
Athira Pharma, Inc.
– Balanced baseline characteristics in ACT-AD and LIFT-AD to date –– Topline data from ACT-AD trial targeted for first half of 2022 – BOTHELL, Wash., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Athira...
The Alzheimer’s disease market is anticipated to grow at an annualized rate of over 13%, till 2030, claims Roots Analysis
27 oct. 2021 07h45 HE
|
Roots Analysis
London, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “Alzheimer's Disease Market (2nd Edition), 2021-2031” report to its list of offerings. Limited treatment...
Athira Pharma to Present Updates from Phase 2/3 Trials of ATH-1017 at the 2021 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
29 sept. 2021 08h05 HE
|
Athira Pharma, Inc.
BOTHELL, Wash., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal...
ANVS BREAKING ALERT: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Annovis Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ANVS
19 août 2021 18h15 HE
|
The Rosen Law Firm PA
NEW YORK, Aug. 19, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of...
CenExel Clinical Research Acquires Advanced Memory Research Institute
19 août 2021 08h12 HE
|
CenExel Clinical Research
Salt Lake City, Utah, Aug. 19, 2021 (GLOBE NEWSWIRE) -- CenExel Clinical Research, Inc., (“CenExel”) announces the acquisition of Advanced Memory Research Institute (“CenExel AMRI”), the largest...
Athira Pharma to Present ATH-1017 Phase 1 Translational Data at the Alzheimer’s Association International Conference 2021 (AAIC)
19 juil. 2021 07h00 HE
|
Athira Pharma, Inc.
BOTHELL, Wash., July 19, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Athira Pharma Announces Initiation of Open Label Extension Study for LIFT-AD and ACT-AD Clinical Trials of ATH-1017 for Alzheimer’s Disease
06 juil. 2021 07h00 HE
|
Athira Pharma, Inc.
BOTHELL, Wash., July 06, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...